에 대한 최신 뉴스 AbbVie (NYSE:ABBV) 주식

AbbVie

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).

Biotech

News

Specialty ETFs

Health Care

Politics

ETFs

General

ABBV

AMGN

SCHD

슈왑 미국 배당주 ETF(NYSE:SCHD)는 12월에 7% 이상 하락하면서 지난 한 달 동안 1년간 상승폭의 절반 이상을 반납했다. SCHD 펀드가 하락한 이유를 살펴보자.

슈왑 미국 배당주 ETF(SCHD), 12월에 7% 이상 하락한 이유는?

Analyst Color

Large Cap

Analyst Ratings

Trading Ideas

ELAN

GILD

IDXX

PRGO

REGN

TEVA

VTRS

JP모건에 따르면 미국 대형 바이오제약주는 2년 연속 전체 시장 대비 저조한 실적을 기록했으며, 2025년에 대한 투자자들의 전망은 혼조세를 보이고 있다. 강력한 펀더멘털과 신약 파이프라인의 발전에도 불구하고 정치적 불확실성과 섹터 순환과 같은 요인으로 인해 S&amp;P 500 대비 바이오제약 섹터의 성과가 저조했다. 

일라이 릴리, 머크 등 대형 바이오제약사 2025년 전망: JP모건

Movers

CACI

LDOS

MNDY

MPWR

MRNA

NVDA

PCVX

SMCI

XPEV

이들 10개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 모놀리식 파워 시스템즈(NASDAQ:MPWR)의 주식은 24.68% 하락했다. 이는 엣지워터 리서치(Edgewater Research)의 분석 보고서에 따라 모놀리식의 엔비디아(NASDAQ:NVDA) 블랙웰(Blackwell) GPU에 대한 할당이 전력 관리 IC의 성능 문제로 위험에 처해 있다고 밝힌 후 발생한 일이다.

슈퍼 마이크로, 모더나 및 샤오펑은 지난주 최악의 성과를 보인 10개 대형주 중 일부 (11월 11일-15일)

AbbVie Inc

AbbVie's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) short percent of float has fallen 3.51% since its last report. The company recently reported that it has 19.32 million shares sold short, which is 1.1% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.62 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>AbbVie Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735131612_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for AbbVie has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing AbbVie's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, AbbVie's peer group average for short interest as a percentage of float is 5.06%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into AbbVie's Recent Short Interest

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) has outperformed the market over the past 5 years by 1.88% on an annualized basis producing an average annual return of 15.25%. Currently, AbbVie has a market capitalization of $317.86 billion. 
Buying $100 In ABBV: If an investor had bought $100 of ABBV stock 5 years ago, it would be worth $201.79 today based on a price of $180.00 for ABBV at the time of writing.
<h3>AbbVie's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735073117_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today

The Schwab US Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) has given back more than half of its one-year gains in the last month, with the ETF falling more than 7% in December. Here's a look at what may be <a href="https://www.benzinga.com/24/12/42528079/this-high-yield-dividend-etf-is-undergoing-a-harsh-reversal-signaling-bearish-trends-here-what-you-need-to-know">plaguing the fund. </a>
What To Know: The Schwab US Dividend Equity ETF is heavily weighted in the healthcare sector with four pharmaceutical stocks representing 15.83% of the fund's total holdings. The sector has underperformed recently as increased uncertainty emerged surrounding the potential appointments and <a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">policy changes</a> that could come under President-elect Donald Trump.&nbsp;
Read Next: <a href="https://www.benzinga.com/general/social-media/24/12/42598651/mystery-drone-sightings-all-over-the-country-trump-says-what-to-know-about-investigations-lawmakers-reactions">&#8216;Mystery Drone&#8217; Sightings Spark Investigations, Politicians Respond: &#8216;Shoot Them Down,&#8217; Trump Says</a>
<h2 class="wp-block-heading">Healthcare Holdings</h2>
Bristol-Meyers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) is the fund's top pharmaceutical holding, representing 4.64% of its assets. The stock is down 2.6% over the past month. 
Pfizer, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is also in the fund's top 10 holdings. It fell more than 5% following the presidential election as the vaccine-maker faces an uncertain political and regulatory environment ahead. 
AbbVie, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Amgen, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) round out the dividend-focused fund's healthcare holdings.  AbbVie shares are down slightly, though Amgen shares are down by more than 10% in December following disappointing <a href="https://www.benzinga.com/content/42377651/amgen-stock-falls-on-weight-loss-drug-data-overreaction-or-fair">clinical trial </a>results from its weight-loss drug candidate, MariTide. 
Interest Rates: Another factor that could be affecting the Schwab dividend-focused fund is the uncertain interest rate environment. Dividends tend to become more attractive to investors in a low-interest rate environment. Recent comments from the Federal Reserve suggest a more hawkish outlook with inflation remaining sticky and above the Fed's target rate of 2%.&nbsp;
Additionally, the incoming Trump administration could again play a factor as Trump has pledged to raise tariffs on foreign imports which could reignite inflation and lead to interest rates staying higher for longer.&nbsp;
When interest rates are high, the yields on bonds and other fixed-income securities become more competitive, making dividend yields less appealing by comparison.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42653466/honda-nissan-plan-to-merge-in-the-face-of-chinese-ev-competition">Honda, Nissan Confirm Merger Plans To Offset Chinese EV Competition: How Mitsubishi Factors In</a></li>
</ul>
Image: Shutterstock

Schwab US Dividend Equity ETF Reverses In December: What's Going On?

According to JP Morgan, U.S. large-cap biopharma stocks have underperformed the broader market for two consecutive years, with mixed sentiment shaping investor outlook for 2025.
Despite strong fundamentals and advancements in drug pipelines, factors such as political uncertainty and sector rotation have hindered the sector's performance relative to the S&amp;P 500.
In 2024, biopharma stocks rose by 9.6%, falling short of the S&amp;P 500's 28.5% surge. However, JP Morgan analysts maintain a positive outlook for several key players.
Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), a top pick for the firm, is projected to see continued growth in its diabetes and obesity treatments, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua" rel="noreferrer noopener">Mounjaro and Zepbound</a>. The analyst also pointed to the company's robust pipeline and forecasted double-digit revenue and earnings growth into the 2030s.
Bristol-Myers Squibb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) has been added to JP Morgan's Analyst Focus List due to the strong potential of its schizophrenia drug, Cobenfy, which could achieve peak sales of $10 billion.
Similarly, Merck &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) are expected to recover in 2025, following challenges in 2024 related to <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38208816/eye-drug-eylea-price-manipulation-regeneron-faces-us-justice-department-allegations-over-medicare" rel="noreferrer noopener">competitive pressures </a>and regional dynamics <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40168774/mercks-blockbuster-vaccine-gardasil-sales-in-china-analyst-highlights-challenges-an" rel="noreferrer noopener">affecting key products</a>.
Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is poised for growth with the anticipated mid-2025 launch of lenacapavir <a target="_blank" href="https://www.benzinga.com/quote/GILD" rel="noreferrer noopener">for HIV prevention</a>.
The firm also highlighted AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) for its appealing valuation, supported by strong Skyrizi and Rinvoq sales despite fewer near-term <a target="_blank" href="https://www.benzinga.com/quote/ABBV" rel="noreferrer noopener">pipeline developments</a>.
Animal health stocks are also projected to rebound in 2025. JP Morgan views Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) as the strongest pick in the sector, citing its potential for high single-digit revenue <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41722660/zoetis-q3-earnings-beat-companion-animal-segment-growth-gives-confidence-into-2025-" rel="noreferrer noopener">growth and margin expansion</a>. IDEXX Laboratories, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) is another solid choice, though its performance depends on a r<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41659873/idexx-laboratories-adjusts-guidance-as-q3-revenue-growth-slows-analyst-notes-fewer-" rel="noreferrer noopener">ecovery in veterinary visits</a>. Meanwhile, Elanco Animal Health Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) faces uncertainties linked to its <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" rel="noreferrer noopener">new product launches</a>.
Specialty pharmaceuticals showed early signs of stabilization in 2024, benefiting from improved pricing stability and supply dynamics. Perrigo Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PRGO#NYSE">PRGO</a>) and Viatris Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTRS#NASDAQ">VTRS</a>) are highlighted as promising opportunities, while Teva Pharmaceuticals Industries Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) may face growth challenges despite delivering strong clinical trial <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42561832/teva-pharmaceutical-releases-impressive-phase-2-candidate-data-for-gastro-related-diseases" rel="noreferrer noopener">results this year</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42623487/jp-morgan-defensive-oil-stocks-to-watch-in-2025-amid-70-brent-forecast" target="_blank" rel="noreferrer noopener">Defensive Oil Stocks To Watch In 2025 Amid $70 Brent Forecast: JP Morgan</a></li>
</ul>
Photo via Shutterstock

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More

On December 18, a recent SEC filing unveiled that Kevin K Buckbee, SVP at AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) made an insider sell.
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001551152/000141588924029754//Archives/edgar/data/1551152/000141588924029754/0001415889-24-029754-index.htm">U.S. Securities and Exchange Commission</a> on Wednesday showed that Buckbee sold 1,800 shares of AbbVie. The total transaction amounted to $310,032. 
AbbVie's shares are actively trading at $172.41, experiencing a down of 0.35% during Thursday's morning session.
<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>Understanding the Numbers: AbbVie's Finances</h3>
Revenue Growth: AbbVie displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 3.83%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 70.87%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): AbbVie's EPS reflects a decline, falling below the industry average with a current EPS of 0.88.
</li>
</ul>
Debt Management: With a high debt-to-equity ratio of 11.78, AbbVie faces challenges in effectively managing its debt levels, indicating potential financial strain.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 60.29 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 5.52 is lower than the industry average, implying a discounted valuation for AbbVie's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): AbbVie's EV/EBITDA ratio, lower than industry averages at 20.27, indicates attractively priced shares.
</li>
</ul>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Relevance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
<h3>The Insider's Guide to Important Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001551152">Check Out The Full List Of AbbVie's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Kevin K Buckbee Executes Sell Order: Offloads $310K In AbbVie Stock

<ul>
<li>The 2024 Canadian Headache Society (CHS) Migraine Prevention Guideline, which replaces the previous version published in 2012, granted strong recommendations for atogepant in episodic and chronic migraine, and for onabotulinumtoxinA in chronic migraine.1</li>
<li>The new CHS Migraine Prevention Guideline is based on a comprehensive systematic review and meta-analysis and addresses both episodic and chronic migraine.1</li>
<li>A strong recommendation was issued when an intervention was deemed suitable for the majority of patients, with benefits outweighing potential risks.1</li>
</ul>
MONTRÉAL, Dec. 19, 2024 /CNW/ - AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)&nbsp;announced today that atogepant and onabotulinumtoxinA&nbsp;have received strong recommendations in the newly updated <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4328408-1&amp;h=3973992059&amp;u=https%3A%2F%2Fwww.headachesociety.ca%2F_files%2Fugd%2F9f0189_8eb9049b4b1943268725ebf41088ea0c.pdf&amp;a=CHS+Migraine+Prevention+Guideline">CHS Migraine Prevention Guideline</a>: atogepant is strongly recommended in the treatment of episodic and chronic migraine, and onabotulinumtoxinA, in the treatment of chronic migraine (please refer to the guideline for the full recommendations). The 2024 version marks a crucial step forward in equipping healthcare professionals with the most current, evidence-based recommendations for preventing and managing migraines – a condition that impacts millions of Canadians.2

AbbVie's Atogepant And OnabotulinumtoxinA Receive Strong Recommendations In The Newly Updated Canadian Headache Society Migraine Prevention Guideline; A Strong Recommendation Was Issued When An Intervention Was Deemed Suitable For The Majority Of Patients, With Benefits Outweighing Potential Risks

WIIM

AbbVie shares are trading higher after Piper Sandler maintained an Overweight rating on the stock and raised its price target from $212 to $220.

Piper Sandler analyst Christopher Raymond maintains AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Overweight and raises the price target from $212 to $220.

Price Target

Piper Sandler Maintains Overweight on AbbVie, Raises Price Target to $220

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.
<h3 class="wp-block-heading">CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>)</h3>
<ul>
<li>Dividend Yield: 5.71%</li>
<li>Truist Securities analyst David Macdonald reiterated a Buy rating and cut the price target from $76 to $67 on Nov. 20. This analyst has an accuracy rate of 66%.</li>
<li>UBS analyst Kevin Caliendo maintained a Neutral rating and raised the price target from $60 to $62 on Nov. 7. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On Monday, CVS Health announced early results of maximum tender offer and election of early settlement.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121724&amp;t=be2bearmibe3na1">latest CVS new</a>s. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="902" height="836" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034652/image-141.png" alt="" class="wp-image-695397" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034652/image-141.png 902w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034652/image-141-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034652/image-141-768x712.png 768w" sizes="(max-width: 902px) 100vw, 902px" /></a></figure>
<h3 class="wp-block-heading">Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</h3>
<ul>
<li>Dividend Yield: 4.44%</li>
<li>B of A Securities analyst Tim Anderson reinstated a Neutral rating with a price target of $63 on Dec. 10. This analyst has an accuracy rate of 61%.</li>
<li>Citigroup analyst Andrew Baum maintained a Neutral rating and raised the price target from $55 to $60 on Nov. 12. This analyst has an accuracy rate of 70%.</li>
<li>Recent News: On Dec. 13, Bristol Myers Squibb said its Board of Directors declared a quarterly dividend of 62 cents per share on the $0.10 par value common stock of the company.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121724&amp;t=be2bearmibe3na1">latest BMY news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="917" height="842" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034734/image-142.png" alt="" class="wp-image-695399" style="width:634px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034734/image-142.png 917w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034734/image-142-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034734/image-142-768x705.png 768w" sizes="(max-width: 917px) 100vw, 917px" /></a></figure>
<h3 class="wp-block-heading">AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</h3>
<ul>
<li>Dividend Yield: 3.82%</li>
<li>B of A Securities analyst Tim Anderson reinstated a Neutral rating with a price target of $191 on Dec. 10. This analyst has an accuracy rate of 61%.</li>
<li>Leerink Partners analyst David Risinger upgraded the stock from Market Perform to Outperform with a price target of $206 on Nov. 22. This analyst has an accuracy rate of 74%.</li>
<li>Recent News: On Dec. 13, AbbVie announced plans to acquire Nimble Therapeutics.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121724&amp;t=be2bearmibe3na1">trend in ABBV stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="915" height="851" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034808/image-143.png" alt="" class="wp-image-695400" style="width:570px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034808/image-143.png 915w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034808/image-143-300x279.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/17034808/image-143-768x714.png 768w" sizes="(max-width: 915px) 100vw, 915px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/12/42507875/how-to-earn-500-a-month-from-worthington-enterprises-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Worthington Enterprises Stock Ahead Of Q2 Earnings</a></li>
</ul>

Dividends

Pre-Market Outlook

Markets

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields

<ul>
<li>Proposed acquisition adds Nimble's lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for psoriasis, and a pipeline of other novel oral peptide assets across autoimmune diseases where significant unmet needs remain</li>
<li>Acquisition also allows AbbVie to utilize Nimble's proprietary peptide synthesis platform to enable the discovery and optimization of oral peptide therapeutics</li>
</ul>
NORTH CHICAGO, Ill. and MADISON, Wis., Dec. 13, 2024 /PRNewswire/ -- AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Nimble Therapeutics today announced a definitive agreement under which AbbVie will acquire Nimble, including its lead asset, an investigational oral peptide IL23R inhibitor in preclinical development for the treatment of psoriasis and a pipeline of other novel oral peptide candidates with potential across several autoimmune diseases. Additionally, AbbVie will acquire Nimble's peptide synthesis, screening, and optimization platform, which uses proprietary technology to help drive rapid discovery and optimization of peptide candidates for a range of targets.
Nimble's preclinical-stage IL23R inhibitor is an investigational oral therapy for the treatment of psoriasis and inflammatory bowel disease (IBD). IL23R is a clinically validated therapeutic target in certain autoimmune diseases and a major contributing factor to psoriasis and IBD pathogenesis and progression through increased inflammation and amplified immune responses.
Under the terms of the agreement, AbbVie will make a cash payment of $200 million at closing to acquire Nimble, subject to certain customary adjustments, in addition to certain interim funding payments. Nimble's shareholders remain eligible for a potential payment, subject to the achievement of a development milestone. The transaction is subject to the satisfaction of customary closing conditions, including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.
Nimble is backed by founding investors Telegraph Hill Partners and Roche Ventures.

AbbVie To Acquire Nimble Therapeutics For $200M In Cash At Closing

19 analysts have expressed a variety of opinions on AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $210.89, a high estimate of $231.00, and a low estimate of $191.00. This upward trend is evident, with the current average reflecting a 2.24% increase from the previous average price target of $206.27.
<img src="https://www.benzinga.com/files/images/story/2024/1733835723_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of AbbVie among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Anderson</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Neutral</td>
<td>$191.00</td>
<td>-</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$206.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$205.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$215.00</td>
<td>$226.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$208.00</td>
<td>$228.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$224.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$221.00</td>
<td>$212.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$226.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Navin Jacob</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$231.00</td>
<td>$218.00</td>
</tr>
<tr>
<td>Andrew Baum</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Evan David Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$220.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Aaron Gal</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Market Perform</td>
<td>$203.00</td>
<td>-</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$215.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Navin Jacob</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$195.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$212.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Steve Scala</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$225.00</td>
<td>$195.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AbbVie. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of AbbVie compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of AbbVie's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABBV/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AbbVie analyst ratings.</a>
<h2>Discovering AbbVie: A Closer Look</h2>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
<h3>Understanding the Numbers: AbbVie's Finances</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: AbbVie's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 3.83%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: AbbVie's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.73% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): AbbVie's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 24.22% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): AbbVie's ROA excels beyond industry benchmarks, reaching 1.09%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 11.78, AbbVie faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Scoreboard: 19 Ratings For AbbVie

B of A Securities analyst Tim Anderson reinstates AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) with a Neutral and announces $191 price target.

Initiation

B of A Securities Reinstates Neutral on AbbVie, Announces $191 Price Target

CNBC Halftime Report Final Trades: AbbVie, Vertiv, iShares Expanded Tech-Software Sector ETF

<ul>
<li>Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH)</li>
</ul>
NORTH CHICAGO, Ill., Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) today announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult patients with diffuse large B-cell lymphoma (DLBCL) at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH).
Arm 1 of the Phase 1b/2&nbsp;EPCORE&#xAE; NHL-2 multi-arm trial evaluates fixed-duration investigational epcoritamab in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in untreated high-risk DLBCL patients (n=46) with International Prognostic Index (IPI) scores of 3 to 5 (Abstract #581).1&nbsp; Results from this arm of the study showed an overall response rate (ORR) of 100% and a complete response (CR) rate of 87%. Among complete responders, an estimated 83% remained in remission after two years. Separately, three-year follow-up results from the Phase 2 EPCORE&#xAE; NHL-1 trial (Abstract #4480),2&nbsp; evaluating epcoritamab monotherapy in challenging-to-treat adult patients (n=157) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy showed that among the 41% of patients who achieved a CR, an estimated 52% were still responding at three years (median CR duration: 36.1 months).
DLBCL is the most common type of non-Hodgkin's lymphoma (NHL) worldwide, accounting for approximately 25-30% of all NHL cases.3,4 In the U.S., there are approximately 25,000 new cases of DLBCL diagnosed each year.5 DLBCL can arise in lymph nodes as well as in organs outside of the lymphatic system, occurs more commonly in the elderly and is slightly more prevalent in men.6,7 DLBCL is a fast-growing type of NHL, a cancer that develops in the lymphatic system and affects B-cell lymphocytes, a type of white blood cell. For many people living with DLBCL, their cancer either relapses, which means it may return after treatment, or becomes refractory, meaning it does not respond to treatment. Although new therapies have become available, treatment management can remain a challenge.6,8

GMAB

AbbVie And Genmab A/S Present Two Data Analyses From Clinical Trials Show Epcoritamab Induces Durable Complete Reponses As Monotherapy And Combination Treatment In Patients With Diffuse Large B-Cell Lymphoma; Results From Arm 1 Of The EPCORE NHL-2 Trial Show Treatment With Epcoritamab Combination Led To An Overall Response Rate Of 100% And A Complete Response Rate Of 87% In High-Risk Patients With Previously Untreated Diffuse Large B-Cell Lymphoma

Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) revealed 10 unusual trades.
Delving into the details, we found 70% of traders were bullish, while 10% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $232,684, and 6 were calls, valued at $237,200.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $125.0 to $185.0 for AbbVie during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for AbbVie's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across AbbVie's significant trades, within a strike price range of $125.0 to $185.0, over the past month.
<h3>AbbVie 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733763664_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$14.6</td>
<td>$14.55</td>
<td>$14.55</td>
<td>$185.00</td>
<td>$115.1K</td>
<td>309</td>
<td align="right">81</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$54.7</td>
<td>$53.25</td>
<td>$54.02</td>
<td>$125.00</td>
<td>$54.0K</td>
<td>30</td>
<td align="right">10</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$4.2</td>
<td>$4.15</td>
<td>$4.17</td>
<td>$170.00</td>
<td>$46.9K</td>
<td>1.6K</td>
<td align="right">115</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.1</td>
<td>$7.5</td>
<td>$8.1</td>
<td>$180.00</td>
<td>$40.5K</td>
<td>2.7K</td>
<td align="right">208</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$8.0</td>
<td>$180.00</td>
<td>$40.0K</td>
<td>2.7K</td>
<td align="right">158</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
After a thorough review of the options trading surrounding AbbVie, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of AbbVie</h3>
<ul>
<li>With a volume of 1,167,374, the price of ABBV is up 0.56% at $177.18. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 53 days.</li>
</ul>
<h3>What Analysts Are Saying About AbbVie</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $211.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Leerink Partners upgrades its rating to Outperform with a revised price target of $206. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on AbbVie with a target price of $215. 
&#x2A; Reflecting concerns, an analyst from Wolfe Research lowers its rating to Outperform with a new price target of $205. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for AbbVie, targeting a price of $224. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on AbbVie, which currently sits at a price target of $208. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for AbbVie, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Check Out What Whales Are Doing With ABBV

On Monday, AbbVie&nbsp;Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) revealed topline results from its pivotal Phase 3 TEMPO-2 trial, which evaluated investigational tavapadon as a flexible-dose monotherapy in <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42387710/abbvie-announces-positive-topline-results-for-the-phase-3-tempo-2-trial-evaluating-tavapadon-as-a-" rel="noreferrer noopener">early Parkinson's disease</a>.
Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease.
The TEMPO-2 trial evaluated the efficacy, safety and tolerability of a flexible-dose (5 mg to 15 mg, once daily) treatment with tavapadon as a monotherapy in adults with early Parkinson's disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42192908/alectorabbvie-partnered-alzheimers-drug-disappoints-in-mid-stage-study-lays-off-17-of-workforce" rel="noreferrer noopener">Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce</a>
The trial met its primary endpoint – patients treated with tavapadon experienced a statistically significant reduction (improvement) from baseline compared to placebo (placebo: -1.2; tavapadon 5-15 mg: -10.3; p-value &lt;0.0001 versus placebo) in the Movement Disorder Society &#8211; Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III combined score at week 26.
The MDS-UPDRS was developed to evaluate various aspects of Parkinson's disease including non-motor and motor experiences of daily living and motor complications.
The TEMPO-2 trial also met the key secondary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor aspects of experiences of daily living (MDS-UPDRS Part II) in the tavapadon group (5-15 mg) compared to placebo at week 26.
The safety profile observed in the TEMPO-2 trial was consistent with prior clinical trials. The majority of adverse events reported were mild to moderate in severity.
Full results from the TEMPO-2 trial will be submitted for presentation at a future medical meeting. AbbVie is on track to submit the New Drug Application to the FDA in 2025.
Last month, AbbVie reported two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41915173/abbvies-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio" rel="noreferrer noopener">two Phase 2 trials</a>.
The studies did not meet their primary endpoint of showing a statistically significant improvement in the change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score compared to the placebo group at week 6.
Price Action: ABBV stock is up 0.86% at $177.71 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/12/42392555/third-largest-ad-firm-omnicoms-interpublic-multi-billion-dollar-deal-could-topple-wpp-as-top-ad-company-but-regulatory-scrutiny-expected" target="_blank" rel="noreferrer noopener">Omnicom Inks $13 Billion Deal For Interpublic: Will It Topple WPP As Top Ad Company?</a></li>
</ul>
Photo via Shutterstock

AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study

<ul>
<li>Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III combined score at week 261</li>
<li>Trial also met its key secondary endpoint, demonstrating statistically significant improvement from baseline in the&nbsp;MDS-UPDRS Part II score at week 261</li>
<li>Positive results across all three Phase 3 TEMPO trials demonstrate the potential of&nbsp;tavapadon as a first-in-class D1/D5 partial agonist in Parkinson's disease</li>
<li>AbbVie is on track to submit an NDA for tavapadon to the FDA in 2025</li>
</ul>
NORTH CHICAGO, Ill., Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson's disease. Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease.
The TEMPO-2 trial evaluated the efficacy, safety and tolerability of a flexible-dose (5 mg to 15 mg, once daily) treatment with tavapadon as a monotherapy in adults with early Parkinson's disease. The trial met its primary endpoint – patients treated with tavapadon experienced a statistically significant reduction (improvement) from baseline compared to placebo (placebo: -1.2; tavapadon 5-15 mg: -10.3; p-value &lt;0.0001 versus placebo) in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III combined score at week 26.1
The TEMPO-2 trial also met the key secondary endpoint, demonstrating a statistically significant and clinically meaningful improvement in motor aspects of experiences of daily living (MDS-UPDRS Part II) in the tavapadon group (5-15 mg) compared to placebo at week 26.1

AbbVie Announces Topline Results For The Phase 3 TEMPO-2 Trial Evaluating Tavapadon As A Monotherapy For Parkinson's Disease; Tavapadon Met The Primary Endpoint And Also Met Its Key Secondary Endpoint

<ul>
<li>Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH)</li>
</ul>

Reported Saturday, AbbVie Unveils Phase 1b/2 EPCORE NHL-2 Trial Results: Epcoritamab Plus R2 Achieves 96% Overall Response Rate In Relapsed/Refractory Follicular Lymphoma

-New insights show Black, Hispanic, and Asian patients have more negative emotional experiences and outlooks with their chronic lymphocytic&nbsp;leukemia (CLL) diagnosis and treatment journeys -CLL is one of the most common leukemias among adults affecting more than 200,000 people in the U.S.1,2

Reported Sunday, AbbVie's Emotional Impact Report Reveals Mental Health Challenges Faced By Diverse CLL Patient Populations At ASH 2024

Financial giants have made a conspicuous bullish move on AbbVie. Our analysis of options history for AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) revealed 13 unusual trades.
Delving into the details, we found 46% of traders were bullish, while 30% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $276,786, and 6 were calls, valued at $363,437.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $150.0 to $200.0 for AbbVie over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for AbbVie's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of AbbVie's whale activity within a strike price range from $150.0 to $200.0 in the last 30 days. 
<h3>AbbVie Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733341561_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$20.05</td>
<td>$19.6</td>
<td>$19.87</td>
<td>$160.00</td>
<td>$135.1K</td>
<td>2.9K</td>
<td align="right">71</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$24.55</td>
<td>$24.3</td>
<td>$24.55</td>
<td>$160.00</td>
<td>$68.7K</td>
<td>43</td>
<td align="right">28</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$1.74</td>
<td>$1.63</td>
<td>$1.64</td>
<td>$182.50</td>
<td>$50.6K</td>
<td>716</td>
<td align="right">499</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.6</td>
<td>$9.4</td>
<td>$9.6</td>
<td>$175.00</td>
<td>$48.0K</td>
<td>1.3K</td>
<td align="right">67</td>
</tr>
<tr>
<td>ABBV</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.85</td>
<td>$6.45</td>
<td>$6.42</td>
<td>$150.00</td>
<td>$46.9K</td>
<td>830</td>
<td align="right">299</td>
</tr>
</tbody>
</table>

<h3>About AbbVie</h3>
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
In light of the recent options history for AbbVie, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is AbbVie Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 2,777,110, with ABBV's price down by -2.71%, positioned at $176.59.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 58 days.</li>
</ul>
<h3>What The Experts Say On AbbVie</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $212.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Showing optimism, an analyst from Leerink Partners upgrades its rating to Outperform with a revised price target of $206. 
&#x2A; Consistent in their evaluation, an analyst from BMO Capital keeps a Outperform rating on AbbVie with a target price of $208. 
&#x2A; Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for AbbVie, targeting a price of $224. 
&#x2A; An analyst from Wolfe Research downgraded its action to Outperform with a price target of $205. 
&#x2A; An analyst from Guggenheim persists with their Buy rating on AbbVie, maintaining a target price of $221. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for AbbVie with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

For years, pharmacy benefit managers took payments from opioid manufacturers, including Purdue Pharma, in return for not restricting the flow of pi...

PBMs took payments from manufacturers to allow free flow of opioids, NYT reports

Catch up on the top industries and stocks that were impacted, or were predicted to be impacted, by the comments, actions and policies of President-...

Trump Trade: Analyst says Trump win 'not as positive as you'd think' for Tesla

Retirement-Ready Income: 5 Dividend Gems I'd Buy If I Were 65

Impax Small Cap Fund Q3 2024 Commentary

If I Had To Invest $100,000 In A Dividend Growth Portfolio Right Now, Here's What I Would Buy

SA Asks: Which Big Pharmas are likely to announce big M&A deals?

Bullish option flow detected in AbbVie (ABBV) with 6,252 calls trading, 1.3x expected, and implied vol increasing over 1 point to 22.06%. Jan-25 19...

AbbVie call volume above normal and directionally bullish

Into 2025: Top 8 Stocks I Own And Why (Part II)

Carillon ClariVest Capital Appreciation Fund Q3 2024 Commentary

Since the 1970s, the term "Santa Claus Rally" has been synonymous with rising stock prices during the last five trading days of December and Januar...

Who Will Shine in This Year's Santa Claus Rally?

AAPL

AGEN

AMZN

AVGO

BIIB

BKNG

BMYMP

CDNS

COST

CRSP

EQIX

FLNC

FOMI

GEODF

GNRC

GOLD

GOOG

GOOGL

HCAT

HERC

INSP

KRKNF

LGND

LGNDZ

LGNXZ

LGNYZ

LGNZZ

MPLX

MSCI

MSFT

NBIX

NFLX

PCRX

QUBT

RIVN

TGLS

TMUS

TSLA

TTGT

VCTR

VICI

VRTX

WELL

XLRE

Screenshot 2024-11-13 at 11.54.41 PM

TNXP

Tonix Pharmaceuticals Targets Rapid Migraine Relief With Non-Oral Treatments

Screenshot 2024-05-14 at 6.27.53 PM

BRTX

CYNO

BioRestorative Therapies (NASDAQ: BRTX) Announces Commercial Agreement With Cartessa, Further Expanding Into $75.46 Billion Aesthetics Market

Screenshot 2024-02-24 at 12.03.42 AM

AXSM

New Drug Study Shows Improving Sleep Quality Can Relieve Fibromyalgia Pain

Press Releases

Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products

AbbVie to Present at Citi's 2024 Global Healthcare Conference

Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients

AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease

Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma

AbbVie Completes Acquisition of Aliada Therapeutics

AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline

AbbVie's atogepant and onabotulinumtoxinA receive strong recommendations in the newly updated Canadian Headache Society (CHS) Migraine Prevention Guideline

Comments

AbbVie

뉴스

에 대한 최신 뉴스 AbbVie (NYSE:ABBV) 주식

화요일, 12월 24, 2024

월요일, 12월 23, 2024

일요일, 11월 17, 2024

금요일, 11월 15, 2024

일요일, 7월 21, 2024

일요일, 7월 07, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌